

החברה הישראלית
לחקר הכבד
Israel Association for the
Study of the Liver




Annual Meeting

23-26.5.2018

Dan Hotel, Eilat

Scientific Program



WEDNESDAY MAY 23rd, 2018

13:00-15:00 **Registration**

14:00-15:00 **Light Lunch at Registration area**

15:00 **Room Check in** (16:00 at Royal Garden)

15:00-17:00 Liver Forum: Case presentations and discussion

Moderator: Prof. Eli Zuckerman

Sponsored by **abbvie**,  **GILEAD**

15:00-15:30 **A rare cause of hepatomegaly in a young patient**
Dor Shirin, Rabin Medical Center

15:30-16:00 **Much Mystery around HISTORt(i)**
Yaakov Maor, Institute of Gastroenterology & Hepatology,
Kaplan Medical Center

16:00-16:30 **נשהכבד פוגש את הכליה**
Yana Davidov, Liver Disease Center, Sheba Medical Center

16:30-17:00 **אבחנה מעופפת**
Tarek Saadi, Liver Unit, Rambam Health Care Campus

17:00-17:30 Coffee Break and visit at the Medical Exhibition

17:30 -17:40 **Welcome greetings**
Prof. Eli Zuckerman, Chair, IsASL

17:40-19:36 SESSION I:
Drug-Induced Liver Injury (DILI) and Liver Fibrosis
Chairs: Dr. Ehud Zigmond, Dr. Ohad Etzion

17:40-17:52 **Immunotherapy-induced hepatitis: clinicopathological characterization in a series of four cases**
Afif Yaacob, Tarek Saadi, Ella Veitzman
Liver Unit, Rambam Health Care Campus, Israel

WEDNESDAY MAY 23rd, 2018

- 17:52-18:04 **Epigallocatechin 3-Gallate ameliorates lipid and liver injury profile through activation of NK cells in mice model of cholestatic liver fibrosis**
Johnny Amer, Ahmad Salhab, **Rifaat Safadi**
Liver Unit, Hadassah Ein – Kerem, Jerusalem, Israel
- 18:04-18:16 **Macrophage-derived COMMD10 plays important protective role in the resolution of acetaminophen-induced liver injury**
Keren Cohen^{1,2}, Odelia Mouhadeb^{1,2}, Shani Ben Shlomo¹, Nathan Gluck¹, Chen Varol^{1,2}
¹The research center for digestive tract and liver diseases, Sourasky medical center, Israel
²Department of clinical microbiology and immunology, Sackler faculty of medicine, Tel-Aviv University, Israel
- 18:16-18:46 **Update from EASL: DILI Guidelines 2018**
Prof. Oren Shibolet, Director, Gastroenterology Unit, Tel- Aviv Medical Center, Israel
- 18:46-18:58 **Liver injury induced by immune checkpoint inhibitors is patient's oriented and is associated with different histological findings**
Yana Davidov^{1,2}, Oranit Cohen-Ezra^{1,2}, Ella Veitsman^{1,2}, Maria Lihter¹, Itai Kalisky^{1,2}, Ziv Ben-Ari^{1,2}
¹Liver Diseases Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
²Sackler School of Medicine, Tel Aviv University, Israel
- 19:00-19:12 **Sodium taurocholate co-transporting polypeptide (NTCP) as novel checkpoint in NK cells activity in Liver fibrosis**
Johnny Amer, Ahmad Salhab, **Rifaat Safadi**
Liver Unit, Hadassah Ein – Kerem, Jerusalem, Israel

19:12-19:24

Leukemia inhibitory factor induces cholangiocyte proliferation and corrects the impaired bile duct morphogenesis in sortilin-deficient mice following cholestatic liver injury

Einav Hubel-Manor¹, Roy Avraham¹, Elise G Lavoie², Jonathan A Dranoff², Isabel Zvibel¹, **Oren Shibolet¹**

¹The Research Center for Digestive Tract and Liver Diseases, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Israel

²Division of Gastroenterology & Hepatology, University of Arkansas for Medical Sciences, USA

19:24-19:36

The Effectiveness of Measuring Thiopurines Metabolites in Adult Patients with Autoimmune Hepatitis

Tarek Saadi, Worood Yassin, Rimma Kramsky, Afif Yaacob, Vered Ben-Hakoon, Hisham Sholy, Ella Veitzman
Liver Unit, Rambam Health Care Campus, Israel

THURSDAY MAY 24th, 2018

08:15-10:34 SESSION 2:

Liver Cancer and transplantation

Chairs: Dr. Yoram Menachem, Dr. Izhar Levi

- 08:15-08:27 **Hepatitis C virus leaves an epigenetic signature following cure of infection by direct-acting antivirals**
Meital Gal- Tanami, Medicine, BIU, Israel
- 08:27-09:02 **Genetic signature of HCC: clinical applications**
Prof. Jessica Zucman-Rossi, University Paris Descartes, France
- 09:02-09:14 **Hypophosphatemia as an early postoperative indicator of decreased major complications rate after liver resection for colorectal liver metastases**
Yael Berger¹, Eviatar Neshet¹, Riad Haddad¹, Shlomit Tamir², Natalia Goldberg², David Aranovich¹, Daniel Benchimol¹, Hanoch Kashtan¹, Eran Sadot¹
¹Surgical Unit, Beilinson Hospital, Israel
²Radiology, Beilinson Hospital, Israel
- 09:14-09:26 **Fecal microbiota profiles as a diagnostic biomarker in cirrhosis and hepatocellular carcinoma and the impact of lifestyle and nutrition**
Lapidot L^{1,4}, Amir A, Nosenko R⁵, Gayshis B², Likhter M², Ben-Ami D², Harnoy O², Engel T², Kalisky I², Weiss P², Veitsman E², Cohen-Ezra O², Davidov Y², Segev S³, Koren O⁵, **Safran M**^{1,2}, Ben-Ari Z^{1,2,4}.
¹Liver Research Laboratory, ²Liver Diseases Center, ³Medical Screening Unit, Chaim Sheba Medical Center – Tel Hashomer ⁴The Sackler School of Medicine, Tel Aviv University, Tel Aviv, ⁵Faculty of Medicine, Bar-Ilan University, Safed

THURSDAY MAY 24th, 2018

- 09:26-09:38 **Are Patients Treated with Direct Antiviral Agents for HCV Infection at Greater Risk for Extrahepatic Malignancies?**
Tarek Saadi, Rimma Kramsky, Afif Yaacob, Hisham Sholy, Faheem Shehadeh, Vered Ben-Hakoon, Ella Veitzman, Jihad Khoury
Liver Unit, Rambam Health Care Campus, Israel
- 09:38-09:50 **Prevalence and outcomes of a second extrahepatic malignancy among patients with Hepatocellular Carcinoma in an Israeli cohort**
Yoram Menachem, Oren Shibolet, Hadar Maringer
Liver Unit, Sourasky Medical Center, Ichilov Hospital, Tel- Aviv, Israel
- 09:50-10:02 **Resection versus transplant listing for hepatocellular carcinoma in Israel: an intention to treat analysis**
Guy Meyerovich^{1,3}, Ido Nachmany^{1,3}, Yaacov Goykhman¹, Richard Nakache^{1,3}, Oren Shibolet^{2,3}, Yoram Menachem², Helena Katsman², **Rafael Bruck**², Nir Lubezky^{1,3}
From the department of surgery¹ and the institute of Gastroenterology², Tel Aviv Medical Center, Sackler School of Medicine³, The Nicholas and Elizabeth Cathedra of Experimental Surgery, Tel Aviv University, Israel
- 10:04-10:34 **Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit**
Prof. Umberto Cillo, Director, Hepatobiliary & Liver Transplantation Unit, University of Padova, Italy
Sponsored by  **NOVARTIS**

10:34- 10:55 Coffee Break and visit at the Medical Exhibition

THURSDAY MAY 24th, 2018

10:55-12:15 SESSION 3:

HCC and liver transplantation II (continued)

Chairs: Dr. Eyal Ashkenazi, Dr. Marius Braun

10:55-11:15

Resection of HCC in cirrhotics

Dr. Riad Haddad, Carmel Medical Center

11:15-11:25

Case presentation: Transplantation after downstaging of HCC outside Milan - For whom and when

Assaf Issachar, Liver Unit, Rabin Medical Center, Israel

11:25-11:40

Discussion: Down staging, loco-regional treatment, transplantation, anti viral treatment

Panel: Prof. Daniel Azoulay, Prof. Eythan Mor and Prof. Umberto Cillo

11:40-11:52

Meso-Rex bypass for Hilar cancer type 3A – Surgical Innovation with a Multidisciplinary treatment approach

Eylon Lahat¹, Ahmad Jaber¹, Gil Golan², Saif Abu-Mouch⁴, Motti Gutmann¹, Ziv Ben Ari³, Daniel Azoulay^{1,5}

¹Department of General Surgery and Transplantation, Hepatobiliary and Pancreatic Surgery, Tel Hashomer Hospital, Tel Aviv, Israel.

²Department of Radiology, Tel Hashomer Hospital, Tel Aviv, Israel.

³Center of Liver Research and Disease, Tel Hashomer Hospital, Tel Aviv, Israel.

⁴Department of Hepatology, Hillel Yaffe Hospital, Hadera, Israel

⁵Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Henri Mondor, Créteil, France.

11:55-12:15

Living related donor liver transplantation: The Israeli Experience

Prof. Eythan Mor, Rabin Medical Center, Israel

THURSDAY MAY 24th, 2018

12:15-12:45 SESSION 4:

State of the art lecture

Chairs: Dr. Alice HersHKovitz, Dr. Yona Kitay

12:15-12:45

Spatial transcriptomics of the mammalian liver

Dr. Shalev Itzkovitz, Department of molecular cell biology,
Weizmann Institute, Israel

12:50-16:20 SESSION 5:

Cirrhosis and Liver Fibrosis I

Chairs: Prof. Rifaat Safadi, Prof. Rafael Bruck

12:50-13:10

Surgery in patients with chronic liver disease

Prof. Adrian Reuben, Prof. of Medicine Emeritus '15, MUSC, USA

13:10-13:22

Acute hemodynamic response to I.V propranolol during hepatic hemodynamic study in 26 cirrhotic patients with portal hypertension and nonbleeding esophageal varices. Correlation with esophageal bleeding and survival.

Eyal Ashkenazi, Yulia Kovalev, Alex Haimovich, Eli Zuckerman
Liver Unit, Carmel Medical Center, Haifa, Israel

13:22-13:34

Prevalence of minimal hepatic encephalopathy in the patients with fatty liver disease: a pilot study

Nir Bar, Shira Deri, Jenny Rutenburg, Oren Shibolet, **Helena Katchman**, Gastroenterology department, Tel Aviv Sourasky Medical Center, Israel

13:35-14:30 Lunch & Visit at the Medical Exhibition.

Lunch will be at the Hotel's restaurant

THURSDAY MAY 24th, 2018

SESSION 5:

Cirrhosis and Liver Fibrosis - continued

14:30-14:42

Liver Cirrhosis, changing of the etiology

Naim Abu-Freha¹, Najwan Kial², Muhammad Abu Tailakh³, Ali Elšana⁴, Alexander Fich¹, Heba Abu Kaf¹, Ohad Etzion¹

¹ The Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, the Arab Medical Association in the Negev, Beer-Sheva, Israel

² Internal Medicine Ward C, Soroka University Medical Center, Beer-Sheva, Israel

³ Nursing Research Unit, Soroka University Medical Center

⁴ Internal Medicine Ward A, Soroka University Medical Center, Beer-Sheva, Israel

14:45-15:10

Placement of TIPS prior to surgery in patients with portal hypertension

Prof. Daniel Azoulay, Professor of Surgery, Dept HPB and Liver Transplant Surgery Centre Hospitalo-Universitaire Hôpital Henri Mondor, France

15:10-15:22

The Role of Eosinophils in CCl4 induced Liver Fibrosis

Itay Moshkovitz, Ayelet Kaminitz, Debby Reuveni, Chen Varol, Chen Varol, Oren Shibolet, Ehud Zigmond
Tel-Aviv Sourasky Medical Center, The Research Center for Digestive Tract & Liver Diseases, Israel

15:22-15:44

Endoscopic Ultrasound-Guided Angio-Therapy for Gastric Varices: A Single Center Experience

Tawfik Khoury, Muhammad Massarwa, Saleh Daher, Ariel Benson, Eran Israeli Jacob Harold, **Julia Esptein**, Rifaat Safadi
The liver Unit, Institute of Gastroenterology and Liver Diseases, Division of Internal Medicine, Hebrew University-Hadassah Medical Organization, Jerusalem, Israel

THURSDAY MAY 24th, 2018

15:45-15:57

Idiopathic non-cirrhotic portal hypertension: clinical and hemodynamic characteristics and outcome of a cohort of 18 patients

Eyal Ashkenazi¹, Yulia Kovalev¹, Alex Haimovich¹, Assaf Issaschar², Michal Naftaly-Cohen², Orly Sne², Marius Braun², Rifaat Safadi³, Saleh Daher³, Daniel Shouval³, Yona Kitayi⁴, Ruth Hadari⁴, Rawi Hazan⁵, Yoav Luria⁶, Helena Katchman⁷, Oren Shibolet⁷, Michal Karmiel⁸, Eli Zuckerman¹.

¹Liver unit, Carmel Medical Center, Haifa, ²Liver Institute, Rabin Medical Center, Petah Tikva, ³Liver Unit, Institute of Gastroenterology and Liver Diseases, Hadassah Medical Center, Jerusalem, Liver Unit, Meir Medical Center⁴, Liver Unit, ⁵Haemek Medical Center, Afula, ⁶Shaare Zedek Medical Center, ⁷GI and Liver unit Tel Aviv Medical Center, ⁸Liver unit, Naharia Medical Center.

16:00-16:20

Management of non-tumoral PVT in candidates to liver transplantation

Prof. Daniel Azoulay, Professor of Surgery, Dept HPB and Liver Transplant Surgery Centre Hospitalo-Universitaire Hôpital Henri Mondor, France

16:20-16:40 Coffee Break and visit the Exhibit Hall

16:40-18:17 SESSION 6:

Viral Hepatitis I

Sponsored by  GILEAD

Chairs: Prof. Ziv Ben-Ari, Dr. Amir Shlomai

16:40-17:10

The Journey of Sofosbuvir: from a molecule to a drug

Dr. Michael Mertens, Director of Hepatitis Medical Affairs, Gilead EMEA

THURSDAY MAY 24th, 2018

17:10-17:22 **Treatment of hepatitis C among HIV HCV coinfectd patients in a real world setting – on the path to HCV elimination in a single center**

Ella Veitsman¹, Tarek Saadi^{1,3}, Afif Yacoub¹, Rimma Kramsky¹, Vered Ben-Hakoon¹, Yaacov Baruch^{1,3}, Margalit Lorber^{2,3}, Jamal Hassoun², Einat Kedem², Eduardo Shahr^{2,3}

¹Center for Liver Diseases, Rambam Health Care Campus, Israel

²Institute of Immunology, Allergy and AIDS, Rambam Health Care Campus, Israel

³Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel

17:25-17:55 **Update from EASL 2018, HCV guidelines 2018**
Prof. Eli Zuckerman, Chair, IsASL

17:55-18:05 **HCV elimination Program in Israel: to where we are going?**
Mr. Julio Borman, Hetz- Israeli Patients' organization

18:05-18:17 **Awake the dormants: barriers to access to care and cure in patients with chronic HCV infection**
Orly Azulay, Eyal Ashkenazi, Yulia Kovalev, **Eli Zuckerman**
Liver Unit, Carmel Medical Center, Technion, Faculty of Medicine, Haifa, Israel

THURSDAY MAY 24th, 2018

18:20-19:33 SESSION 7:

Viral Hepatitis II

Sponsored by **abbvie**

Chairs: Dr. Seif Abu- Much, Dr. Assaf Issachar

18:20-18:45

Emerging Therapies for hepatitis B: What is expected in the near future?

Prof. Ran Tur-Kaspa, Liver Institute, Rabin Medical Center, Faculty of Medicine in the Galilee, Bar Ilan University, Israel

18:45-18:57

Real life experience with direct acting antiviral agents in patients with chronic hepatitis C and inherited bleeding disorders

Yana Davidov^{1,2}, Oranit Cohen-Ezra^{1,2}, Ella Veitsman¹, Avishag Hassid¹, Dana Silverberg¹, Adi Halle-Bikovski¹, Keren Tzaraf¹, Ziv Ben-Ari^{1,2}

¹Liver Diseases Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

²Sackler School of Medicine, Tel Aviv University, Israel

18:57-19:09

Circulation of hepatitis E in Israel: high prevalence in pigs, Dromedary camels and in specific human populations

Rachel Shirazi¹, Shaul Pozzi², Ravit Bassal³, Dan David², Marina Wax¹, Itay Bar-Or¹, Efrat Asulin¹, Yaniv Lustig¹, Eli Schwartz^{4,5}, Hazzan Rawai⁶, Ella Mendelson^{1,5}, Ziv Ben-Ari^{5,7}, **Orna Mor**^{1,5}

¹Central Virology Laboratory, Ministry of Health, Israel

²Veterinary services, Agriculture Ministry, Israel

³Israel Center for Disease Control, Ministry of Health, Israel

⁴Tropical Diseases, Sheba Medical Center, Israel

⁵Sackler Faculty of Medicine, Tel Aviv University, Israel

⁶Liver unit, Haemek Medical Center, Israel

⁷Liver unit, Sheba Medical Center, Israel

19:09-19:21

Liver steatosis predicts mortality and cancer in patients with chronic hepatitis B infection and is inversely correlated with viral replication

Noam Peleg¹, Assaf Issachar^{1,2,3}, Michal Cohen-Naftaly^{2,3}, Orly Sneh-Arbib^{2,3}, Marius Brown^{2,3}, Amir Shlomai^{1,2,3}

¹Internal medicine D, Rabin Medical Center, Israel

²Institute of Liver Disease, Rabin Medical Center, Israel

³Sackler Faculty of Medicine, Tel Aviv University, Israel

19:21-19:33

High frequency of multiclass HCV resistance to second-generation direct-acting antiviral failure in Israel real-life: tailored therapies are advocated

Ziv Ben-Ari^{1,3}, **Yael Gozlan**², Rachel Shirazi², Aviya Rakovsky², Yana Davidov¹, Ella Veitsman⁴, Tarek Saadi⁴, Marius Braun^{3,5}, Michal Cohen-Naftaly^{3,5}, Amir Shlomai^{3,5}, Oren Shibolet^{3,6}, Ehud Zigmond^{3,6}, Helena Katchman^{3,6}, Yoram Menachem^{3,6}, Rifaat Safadi⁷, Eitan Galun⁷, Eli Zuckerman⁸, Assy Nimer⁹, Rawi Hazzan¹⁰, Yaakov Maor¹, Sayaf Abu-Moch¹², Ohad Etsion¹³, Yoav Lurie¹⁴, Orna Mor^{2,3}

¹Liver unit, Sheba Medical Center, Israel

²Central Virology Laboratory, Ministry of Health, Israel

³Sackler Faculty of Medicine, Tel Aviv University, Israel

⁴Liver unit, Rambam Medical Center, Israel

⁵Liver unit, Rabin Medical Center, Israel

⁶Department of Gastroenterology, Tel-Aviv Medical Center, Israel

⁷Liver unit, Hadassah Medical Center, Israel

⁸Liver unit, Carmel Medical Center, Israel

⁹Internal Medicine department, Galilee Medical Center, Israel

¹⁰Liver unit, Haemek Medical Center, Israel

¹¹Division of Gastroenterology, Kaplan Medical Center, Israel

¹²Liver unit, Hillel Yafe Medical Center, Israel

¹³Liver unit, Soroka Medical Center, Israel

¹⁴Liver unit, Shaare Zedek Medical Center, Israel

THURSDAY MAY 24th, 2018

08:00-09:30 PARALLEL SESSION FOR NURSES - CORAL HALL

פורום אחיות כבד 2018 אילת

Sponsored by  המושב בחסות

התכנסות 07:50

הרצאת פתיחה: "PBC - המחלה והסיבוכים" 08:00
פרופ' אלי צוקרמן, מנהל מכון הכבד במרכז הרפואי כרמל ויו"ר החברה

מקרה לדיון ב PBC 08:50
יעל חריף, אחות אחראית במכון כבד, מרכז רפואי רבין
קרן צארף, אחות אחראית במרכז למחלות כבד, מרכז רפואי שיבא

"תפקיד האחות ב PBC" 09:10
קרן צארף, אחות אחראית במרכז למחלות כבד, מרכז רפואי שיבא

מקרה לדיון OCALIVA 09:30
ד"ר אורנית כהן עזרא, המרכז למחלות כבד, מרכז רפואי שיבא

פעילות עמותת חץ במטופלי מחלות אוטואימוניות של הכבד 09:50
גב' סינדי וינבוים, עמותת חץ

דברי סיכום 10:10
גב' אורלי אזולאי, אחות אחראית ומתאמת מחקרים במכון הכבד,
מרכז רפואי כרמל

08:15-10:22 SESSION 8:

Non-Alcoholic Fatty Liver Disease

Chairs: Prof. Oren Shibolet, Dr. Yaakov Maor

08:15-08:27

Portal Lymphadenopathy Predicts Steatohepatitis and Advanced Fibrosis in Non-alcoholic Fatty Liver Disease

Saleh Daher¹, Tawfik Khoury¹, Namma Lev Cohen², Mira Nasser¹, Mohamad Massarwa¹, Rani Oren¹, Rifaat Safadi¹

¹The Liver Unit, Institute of Gastroenterology and Liver Diseases, Institute of Gastroenterology and Liver diseases, Israel and

²The Department of Radiology, Hadassah University Hospital, Ein Kerem, Israel

08:27-08:39

Serum sRAGE levels are associated with lifestyle and with non-alcoholic fatty liver disease

Dana Ivancovsky^{1,2}, Shira Zelber Sagi^{1,2}, Naomi Fliss Isakov², Muriel Webb^{2,3}, Oren Shibolet^{2,3}, Revital Kariv^{2,3}

¹School of Public Health, University of Haifa, Israel

²Department of Gastroenterology, Tel-Aviv Medical Center, Israel

³The Sackler Faculty of Medicine, Tel-Aviv University, Israel

08:39-08:51

Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mTOR expressions and was correlated with their impaired function

Johnny Amer, Ahmad Salhab, Sarit Doron, **Rifaat Safadi**

Liver Unit, Hadassah Ein Kerem Hospital, Israel

08:51-09:04

Quantification of Hepatic Fat – Ultrasound, Biomarkers and MR Spectroscopy

Yaakov Maor¹, Na'ama Reshef², Assaf Tal³, Hila Knobler²

¹Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Israel, ²The Diabetes and Metabolic Unit, Kaplan Medical Center, Israel, ³Department of Chemistry, The Weizmann Institute, Israel

09:04-09:16

Noninvasive scoring systems predict long-term morbidity, mortality and cancer in patients with nonalcoholic fatty liver disease

Noam Peleg¹, Orly Sneh Arbib², Assaf Issachar^{1,2,3}, Michal Cohen-Naftaly², Marius Braun^{2,3}, Amir Shlomai^{1,2,3}

¹ Department of Medicine D, Rabin medical center, Beilinson hospital, Petach-Tikva, Israel.

² The Liver Institute, Rabin medical center, Beilinson hospital, Petach-Tikva, Israel.

³ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

09:16-09:46

Update from EASL: NASH and emerging therapies

Prof. Ziv Ben-Ari, Liver Unit, Sheba Medical Center, Israel

09:46-09:58

Screening Diabetic Patients for Non-alcoholic Fatty Liver Disease (NAFLD) - Is it Cost-Effective?

Yaakov Maor¹, Shira Zelber-Sagi^{2,3}, Moshe Leshno⁴

¹ Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Israel

² Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Israel

³ School of Public Health, University of Haifa, Israel

⁴ Coller School of Management, Tel Aviv University, Israel

9:58-10:10

The pattern of elevated liver function tests in non-alcoholic fatty liver disease predicts fibrosis stage and metabolic-associated comorbidities

Dor Shirin¹, Noam Peleg^{1,2}, Orly Sneh-Arbib², Michal Cohen-Naftaly², Marius Braun^{2,3}, Assaf Issachar^{1,2} and Amir Shlomai^{1,2,3}

¹ Department of Medicine D, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel

² The Liver Institute, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel

³ The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

FRIDAY MAY 25th, 2018

10:10-10:22 **NAFLD fibrosis score predicts diabetic complications in patients with NAFLD**

Noam Peleg¹, Assaf Issachar^{2,3}, Sneh-Arbib Orly^{2,3}, Michal Cohen-Naftaly^{2,3}, Marius Brown^{2,3}, Amir Shlomai^{2,3}

¹Internal medicine D, Rabin Medical Center, Israel

²Institute of Liver Disease, Rabin Medical Center, Israel

³Sackler Faculty of Medicine, Tel Aviv University, Israel

10:22-10:40 Coffee Break and visit the Medical Exhibition

10:40-10:45 Awards for outstanding clinical study, basic science study & poster

10:45-12:18 SESSION 9:

Cirrhosis and Liver fibrosis II

Chairs: Dr. Tarek Saadi, Dr. Ella Weitzman

10:45-11:05 **Kidney injury in patients with cirrhosis**

Prof. Adrian Reuben, Prof. of Medicine Emeritus ¹US, MUSC, USA

11:05-11:17 **Hepatocyte-secreted exosomes can inhibit and reverse hepatic stellate cells stimulation**

Ben-Ari Ziv^{1,3}, Masoud Rola¹, Sultan Maya¹, Tachlytski Irena¹, Balint-Lahat Nora², Pappo Orit², Safran Michal¹

¹Liver Diseases Center, ²Pathology department Chaim Sheba Medical Center Sackler School of Medicine, Tel Aviv University, Tel Aviv

³Sackler School of Medicine, Tel Aviv University, Tel Aviv

11:17-11:29 **COMMD10 is important for Kupffer cell elimination of Staphylococcus aureus**

Chen Varol, Shani Ben Shlomo, Odelia Mouhadeb, Nathan Gluck
The Research Center for Digestive Tract & Liver Diseases, Sourasky Medical Center and Tel Aviv University, Israel

11:30-11:42

Liver Cirrhosis, Etiology and Clinical Characteristics Disparities among minority population

Muhammad Abu Tailakh², Liat Poupko³, Najwan Kial⁴, Ali Elsana⁵, Ohad Etzion¹, Heba Abu KafI, Alexander Fich I, David Yardni I, Anat Nevo-Shor¹, Abed Abu Ganim⁶, **Naim Abu-Freha**¹

¹ Nursing Research Unit, Soroka University Medical Center, Epidemiology Department, Ben-Gurion University, Beer-Sheva, Israel

² 1st years student, Medical School for International Health, Ben-Gurion University, Beer-Sheva, Israel

³ Internal Medicine Ward C, Soroka University Medical Center, Beer-Sheva, Israel.

⁴ Internal Medicine Ward A, Soroka University Medical Center, Beer-Sheva, Israel.

⁵ The Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

⁶ Surgical Ward A, Soroka University Medical Center, Beer-Sheva, Israel.

11:42-11:54

The anti fibrotic effect of Aramchol on rat liver fibrosis induced by TAA and in vitro on primary hepatic stellate cells.

Regina Golan-Gerstl, Nickolay Koroukhov, Rawand Khweiss, **Shimon Reif**

Pediatrics Department, Hadassah Medical Center, Israel

11:54-12:06

Elevated expressions of Sodium taurocholate co-transporting polypeptide (NTCP) on NK cells impaired their function and contribute to liver fibrosis

Johnny Amer, **Rifaat Safadi**, Ahmad Salhab
Liver Unit, Hadassah Ein Kerem Hospital, Israel

FRIDAY MAY 25th, 2018

12:06-12:18 **The direct effect of the citric acid cycle on hepatic stellate cell activation and on the development of liver fibrosis**
Landesman H^{1,2}, Tachlytski I¹, Masoud R¹, Ben-Ari Z^{1,2}, Safran M¹
¹Liver Diseases Center, ²Sackler School of Medicine, Tel Aviv University, Tel Aviv

12:18-12:40 **Business Meeting**

13:30 **Lunch at Hotel's Restaurant**

PARALLEL SESSION: NURSES FORUM 8:30-11:15

Coral Hall

מושב אחיות מקביל- אולם קורל

Sponsored by  GILEAD המושב בחסות

האם ישראל יכולה להפוך למדינה ללא הפטיטיס סי? 08:30-09:15
פרופ' אלי צוקרמן

קח את התרופה)- מעבר מתקשורת 09:15-10:45
Принимайте лекарство!
HCV - אינפורמטיבית לאפקטיבית עם חולי
מיכה שנהב, מרכז טל

כל אחד יכול להחלים - מיקרואלימינציה בקרב משתמשי סמים 10:45-11:15
ד"ר ניצן גל, חברת גילייד

INVITED SPEAKERS



Prof. Jessica Zucman-Rossi

University Paris Descartes, France

Jessica Zucman-Rossi is Professor of Medicine at University Paris Descartes, within the department of Oncology at the European Hospital Georges Pompidou (AP-HP). She is the director of an INSERM laboratory "Functional Genomics of Solid Tumors", with a focus on liver, mesothelial and renal tumors. Her team aims to develop basic genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis and to transfer this knowledge into biomarkers that could be introduced in clinical care. In particular, the group was pioneer in the elucidation of the molecular classification of benign and malignant liver tumors. Currently, she is executive secretary of ILCA (International Liver Cancer Association) and she acts as co-Editor for Journal of Hepatology.

INVITED SPEAKERS



Prof. Adrian Reuben

Adrian Reuben is Professor of Medicine Emeritus' 15 at the Medical University of South Carolina (MUSC), in Charleston SC, where, during 1993-2014, he directed the Liver Program he created.

Dr. Reuben graduated in Medicine, completed Residency and Gastroenterology Fellowship in London UK, before completing a scholarship at Yale. After a Yale faculty appointment (1981-1993), he moved to MUSC to establish the Liver Service and enhance the fledgling Liver Transplant (LT) program

His continues research on Acute Liver Failure (ALF), Coagulopathy in Liver Disease, Alcohol Biomarkers, Non-Invasive Investigation of Liver Disease and Drug Hepatotoxicity. He has considerable experience in LT, portal hypertension and he edited the May 2015 issue of Clinics in Liver Disease on Hepatocellular Carcinoma. He previously pursued laboratory-based investigation of biliary lipid secretion, and hepatic fibrogenesis. He has published 100+ peer-reviewed articles, editorials, case reports, and book chapters, as well as 44 essays in the acclaimed Landmarks in Hepatology series

He has presented at national and international meetings, taught in postgraduate courses and workshops, and lectured in three continents. His participation in American Association for the Study of Liver Diseases (AASLD) committees, includes the Ethics Committee of which he was also the Chair. He continues to lecture, perform and publish research, review manuscripts and grant applications, and write chapters and reviews. His interest in drug hepatotoxicity is exemplified by an original article in HEPATOLOGY, on Drug-Induced Liver ALF in the United States, chapters in hepatotoxicity textbooks and membership of the Hepatotoxicity Special Interest Group Steering Committee of the AASLD. He has also first-authored a recent 16-year overview of ALF experience by the US ALF Study Group, published in April 2016 in Annals of Internal Medicine. Finally, he has very close connections with Medicine in Israel, and with Israeli Hepatology in particular. He and his late wife spent a delightful 6-month sabbatical at Hadassah in 2011/2012, and he continues to visit Israel frequently, when he lectures and teaches at major Israeli medical centers. He also has reasonable conversational Hebrew

INVITED SPEAKERS



Prof. Umberto Cillo

MD, FEBS, Professor of General Surgery

Director, Hepatobiliary and Liver Transplantation Unit

University of Padova, Italy

He is Professor of General Surgery at the Department of General Surgery, University of Padova since 2011 and Director of the Hepatobiliary and Liver Transplantation Unit, Department of General Surgery at the University of Padova since 2004.

He is President of the Italian Society of Organ Transplantation (SITO) and the Italian representative of the European Board of Surgery, section of Transplantation (UEMS).

Member of ESOT (European Society for Organ Transplantation) Council.

He will be President of the ESOT (European Society for Organ Transplantation) Congress in Milan, 2021.

Prof Cillo has performed as first surgeon/tutored over 3500 interventions of general surgery, over 1000 liver transplants, more than 140 cases of pediatric liver transplantation including split child-adult and adult-adult, living donor.

He performed the first auxiliary liver transplantation in Italy (2007) and the first liver autotransplantation (2011) in Italy.

Since 2004 more than 2300 liver resections, 1200 liver transplants and 3600 liver ablations have been performed in his Unit.

Prof Cillo is first author or co-author of 277 reviewed publications, 18 chapters and 4 monographs. I.F. (JCR) 1213,626, H-INDEX 40 (Scopus), 48 (Google Scholar)

INVITED SPEAKERS



Prof. Daniel Azoulay

Professor of Surgery, Dept HPB and Liver Transplant Surgery
Centre Hospitalo-Universitaire Hôpital Henri Mondor, France

Prof. Daniel Azoulay is one of the world's leading surgeons in the field of complex liver surgeries and liver transplants.

Prof. Daniel Azoulay completed his medical studies at the University of Paris, and for 22 years he was a senior surgeon at the Hepatobiliary Center, founded by Professor Henry Bismuth at Paul Brousse Hospital. For seven years he has been Chief Department of Digestive, Hepato-Pancreato-Biliary and Liver Transplantation Surgery Hôpital Henri Mondor (University Hospital) – Assistance Publique-Hôpitaux de Paris.

To date, he has performed more than 1,500 liver transplants from dead and live donors and thousands of liver-pancreatic-biliary surgeries, some of which are highly complex.

Prof. Azoulay likes to teach and share his rich practical experience with medical students. He is a member of the European Society of Surgery and Liver Transplantation and has published more than 400 medical articles in the leading medical literature. He has also served as editor in major medical journals in the field of general surgery, liver and transplantation, including Annals of Surgery, British Journal of Surgery, and World Journal of Surgery.

His extensive experience in liver and pancreatic surgery includes in situ hypothermic perfusion of the Liver, surgical shunts, liver ablation in the front and split liver transplantation.

SPONSORED BY

Platinum



GILEAD

Advancing Therapeutics.
Improving Lives.

Diamond

abbvie



MSD

INVENTING FOR LIFE

Gold



NEOPHARM ISRAEL

NEOPHARM GROUP

Silver



מגזר תרופות ביניים



NOVARTIS

Organized by:



ORTRA

MEETING POINT